Moderna, Inc. (accesswire)

Moderna, Inc.: Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day

EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna’s Omicron-Targeting Bivalent Booster in the European Union

Moderna, Inc.: Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214

Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna’s Omicron-Containing Bivalent Booster in the UK

Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses

EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union

Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement

Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union